What do the studies show?

KLOW peptide research draws on studies of tissue repair, collagen production, inflammation and hair-follicle activity. Human research includes trials of specific topical preparations and a small knee-pain report. Laboratory work covers a wider range of outcomes, including muscle strength, bone healing, nerve regeneration and blood-vessel formation.

This review explains research findings on KLOW’s ingredients and related thymosin peptides. Start with the findings below, then use the topic links to reach the study explanations. For an overview organized around potential benefits, see our KLOW peptide benefits article.

Human studies at a glance

Human findings from specific peptide preparations
Research areaStudy findings
Knee painHuman records: 14 of 16 people reached for follow-up reported relief after BPC-157, sometimes combined with thymosin beta-4. There was no control group.1
Skin appearance and ulcersTopical GHK-Cu trials: ulcer-area closure improved; after laser treatment, satisfaction improved without a significant difference in objective skin ratings.14, 15
Dry eyeThymosin beta-4 eye drops, 72 people: no significant difference in the two main outcomes; some secondary findings favored treatment.25

Cell and animal studies at a glance

Laboratory findings, with the research model identified
Research areaStudy findings
Tendon and ligament repairRat injury studies: stronger healing tissue and better function. A separate BPC-157/TB-500 experiment found no added advantage from combining them.2, 3, 4, 5
Muscle repairBPC-157 rat studies: improved strength or function after cut and crush injuries.6, 7
Bone repairBPC-157 rabbit study: improved healing of a surgically created bone defect.8
Peripheral nerve repairBPC-157 rat study: improved nerve regeneration, electrical responses and walking function after sciatic-nerve injury.9
Blood-vessel formationBPC-157 cell and animal experiments: increased vessel formation and faster blood-flow recovery in a rat limb with restricted circulation.10
Collagen, wounds and burnsCell and animal work: several peptides improved collagen or wound-healing measures. GHK-Cu did not improve outcomes in one irradiated-wound model.16, 18, 13
Intestinal inflammationKPV and GHK-Cu cell and mouse studies: reduced inflammatory signals and tissue injury; some experiments examined delivery or lining repair.21, 22, 19
Skin inflammationMouse experiments with alpha-MSH peptides, including the KPV fragment: reduced acute swelling and contact-sensitivity responses.23
Antimicrobial activityLaboratory experiments: KPV and related alpha-MSH peptides reduced bacterial colony formation and yeast viability.24
Hair-follicle activityFull-length thymosin beta-4: increased hair growth in rodents and activity in isolated follicle cells.28
Lung inflammationGHK-Cu pretreatment in mice: reduced inflammation and lung damage following an experimental inflammatory challenge.20
Heart and brain injuryFull-length thymosin beta-4: improved cardiac outcomes in mice and neurological recovery in rats. These are related-peptide studies.29, 30

What do the human studies show?

GHK-Cu and diabetic foot-ulcer healing

Mulder’s 1994 randomized, evaluator-blinded trial compared topical GHK-Cu gel with its inactive vehicle. Both groups received wound care and footwear that reduced pressure on diabetic neuropathic ulcers. The median reduction in plantar ulcer area was 98.5% with GHK-Cu versus 60.8% with the vehicle.14

Those figures describe how much the ulcer area shrank, rather than the percentage of patients who healed completely. The result supports further investigation of that topical preparation alongside wound care.

BPC-157 and reported knee-pain relief

Lee and Padgett’s 2021 report reviewed treatment records and telephone follow-up. Eleven of 12 people who received BPC-157 alone and three of four who also received thymosin beta-4 reported relief.1

That is an encouraging patient-reported finding, but there was no untreated comparison group and follow-up timing varied. The report cannot establish how much improvement the peptides caused or whether the joint’s structure healed.

GHK-Cu and skin appearance after laser treatment

Miller’s 2006 randomized study compared skin-care regimens with and without GHK-Cu after CO2 laser resurfacing. Thirteen people completed the study. At 12 weeks, GHK-Cu users reported greater satisfaction, while blinded assessments found no significant advantage in wrinkles, redness or overall skin quality.15

Both groups improved after laser treatment. The additional benefit patients felt was not matched by a clear difference in the objective skin ratings.

Thymosin beta-4 and dry-eye outcomes

Sosne and Ousler’s 2015 trial compared thymosin beta-4 eye drops with placebo in 72 people. At day 29, the two primary outcomes—eye discomfort and damage detected by corneal staining—did not differ significantly. Some secondary outcomes favored thymosin beta-4.25

The primary outcomes were the planned tests of success. The secondary findings offer leads for further research, but do not make this a clearly positive trial overall.

What do injury-repair studies show?

Tendon and ligament strength

Three BPC-157 rat studies measured physical healing across different injuries:

  • Severed Achilles tendon: Staresinic’s 2003 study reported better function, stronger tendons and more organized repair tissue over 14 days.2
  • Tendon attachment to bone: Krivic’s 2006 experiment detached the Achilles tendon from the heel. Over 21 days, treated groups showed better function, collagen organization and resistance to loading.3
  • Knee ligament: Cerovecki’s 2010 study followed a cut medial collateral ligament for up to 90 days and reported improved function, mechanical properties and tissue organization.4

Several investigators appear across these papers. The studies broaden the injury models, but do not represent three wholly independent research teams. Their follow-up periods describe rat healing, not human recovery timelines.

Muscle repair after cut and crush injuries

Staresinic’s 2006 experiment followed rats with a completely cut quadriceps muscle for up to 72 days. BPC-157 improved the force the healing muscle could withstand before failure, walking function and muscle-fiber regeneration.6

Novinscak’s 2008 study examined a crush injury over 14 days. It reported improved functional and microscopic healing, with less swelling and contracture.7 Together, these studies add measured muscle-repair outcomes to the recovery discussion. They involved severe injuries and did not test muscle growth from exercise.

Bone repair across a defect

Sebecic’s 1999 rabbit experiment examined healing across a surgically created gap in the radius. BPC-157 improved bone-defect healing compared with controls.8 This adds bone formation to the tissue-repair evidence, although it does not answer whether KLOW changes bone density or fracture recovery in people.

Peripheral nerve regeneration

Gjurasin’s 2010 study examined BPC-157 after sciatic-nerve injury in rats. Researchers assessed regenerated nerve fibers, electrical responses and walking function. The treated groups showed faster regeneration and improved functional recovery.9

The useful point is that the study measured both nerve structure and function. It investigated traumatic peripheral-nerve repair, rather than everyday sciatica or general cognitive performance.

Repair-cell movement and blood supply

Chang’s 2011 tendon-cell experiments found that BPC-157 increased cell outgrowth and movement and improved survival under oxidative stress. It did not directly increase cell proliferation in the assay used.11 Helping repair cells move and survive is one possible part of healing.

Hsieh’s 2017 study examined another: blood supply. BPC-157 increased vessel formation in cell and animal experiments and accelerated blood-flow recovery in rats whose hind limbs had a restricted blood supply. The researchers linked these effects to VEGFR2 signaling, a pathway involved in blood-vessel growth.10

BPC-157 and TB-500, alone and together

Biçer’s 2026 experiment compared BPC-157, TB-500, both peptides and a control after Achilles repair in 32 rats. At four weeks, the TB-500 group’s tendons resisted more force before breaking: a median 37.4 N versus 26.9 N in controls. The BPC-157 difference was not statistically significant, and combining the peptides showed no added advantage.5

Only four tendons per group underwent strength testing. The authors describe their TB-500 material as synthetic thymosin beta-4. This small experiment directly tested a combination, but cannot settle which peptide works better.

What do skin and wound-healing studies show?

Seiwerth’s 1997 BPC-157 experiments covered skin incisions, surgically joined intestine and tissue growing into implanted sponges in rats. Healing measures involving collagen, blood vessels and tissue strength improved.12 Later studies examined specific repair processes and more difficult wounds.

GHK-Cu and collagen formation

Maquart’s 1988 cell-culture study found increased collagen production in fibroblasts, independently of cell number. The group’s 1993 rat experiment also found greater accumulation of collagen and other supporting material in implanted wound chambers.16, 17

The result differed in Parker’s 2013 irradiated-wound study. Topical copper-peptide gel did not significantly improve healing or the measured blood-vessel outcomes under the study’s statistical criteria.18 Increased collagen production in one setting does not predict success in every wound.

BPC-157 and burn-wound healing

Mikus’s 2001 mouse study assessed deep partial-thickness burns. Topical BPC-157 improved skin-surface closure, collagen organization and the strength of healing skin, while reducing swelling and inflammatory-cell numbers.13 Measuring strength alongside appearance made this more informative than a visual healing comparison alone.

Thymosin beta-4 and rebuilding the skin’s surface

Malinda’s 1999 experiments found increased skin-surface coverage, wound contraction, collagen deposition and vessel formation in rats given thymosin beta-4. Keratinocytes—the cells that rebuild the skin’s surface—also moved more in cell experiments.26

Philp’s 2003 study extended the work to diabetic and aged mice, reporting improved wound contraction and collagen deposition. The seven-amino-acid sequence LKKTETQ also promoted repair in aged mice.27 That result concerns a particular fragment as well as the full-length peptide.

What do inflammation and antimicrobial studies show?

KPV and intestinal inflammation

Dalmasso’s 2008 study examined human intestinal and immune cell cultures and two mouse colitis models. KPV entered cells through PepT1, a peptide transporter, reduced inflammatory signaling and lessened intestinal inflammation in mice.21

Laroui’s 2010 study then tested KPV carried in colon-targeted nanoparticles. The formulation reduced inflammation in a mouse colitis model.22 This paper adds a delivery question: how much of the peptide reaches the tissue being studied?

GHK-Cu and the intestinal lining

Mao’s 2025 study also examined experimental colitis. GHK-Cu reduced inflammation and supported repair of the intestinal lining. The researchers also examined proteins that help seal gaps between intestinal cells.19 It studied GHK-Cu rather than a GHK-Cu/KPV combination.

KPV-related peptides and skin inflammation

Hiltz and Lipton’s 1990 mouse experiments tested alpha-MSH peptides, including its C-terminal KPV fragment, in acute paw swelling and contact-sensitivity models. They reported reduced inflammatory responses.23 This extends the KPV discussion beyond the intestine, while keeping the particular experimental peptides and models in view.

KPV and antimicrobial activity

Cutuli’s 2000 laboratory study tested alpha-MSH and its KPV fragment against Staphylococcus aureus and Candida albicans. The peptides reduced bacterial colony formation and yeast viability, including germ-tube formation associated with Candida growth.24

These are direct laboratory measurements of antimicrobial activity. The study did not test treatment of infections in people.

GHK-Cu and inflammatory lung injury

Park’s 2016 study gave mice GHK-Cu before an experimental inflammatory challenge. Pretreatment reduced lung-injury scores, inflammatory responses and tissue leakage. Cell experiments also found reduced oxidative stress.20 The timing matters: the experiment tested protection before the challenge, rather than treatment of established human lung disease.

Is there research on hair-follicle activity?

Philp’s 2004 study reported increased hair growth in normal rats and mice exposed to full-length thymosin beta-4. Cells isolated from rat whisker follicles also showed increased movement and differentiation associated with follicle activity.28

This gives the hair-growth discussion an experimental basis, although it was not a human hair-loss trial and did not test KLOW.

What does related thymosin beta-4 research add?

Two further studies broaden the tissue-repair question. Both used full-length thymosin beta-4, so their results should remain separate from claims about a shorter TB-500 fragment or the complete KLOW blend.

  • Heart injury: Bock-Marquette’s 2004 mouse study reported improved early heart-cell survival and cardiac function after experimentally induced injury.29
  • Brain injury: Xiong’s 2012 rat study began treatment six hours after traumatic injury. It reported better sensorimotor recovery and spatial learning, alongside smaller cortical lesions and reduced hippocampal cell loss.30

These papers are useful examples of how repair research measures organ function alongside tissue changes. They do not establish that the different thymosin-related molecules have interchangeable effects.

Sources and study selection

This review draws on original human, cell and animal research. It focuses on measured repair and inflammatory outcomes, including mixed findings and results from related thymosin molecules. Summaries draw on original papers or their abstracts; this is not a systematic review. The product listing provides the formula reference. Research checked September 11, 2026.

BPC-157 and combination studies

  1. Lee E, Padgett B. BPC-157 for knee pain: a retrospective clinical report. Alternative Therapies in Health and Medicine. 2021;27(4):8–13.
  2. Staresinic M, et al. BPC-157 and healing of transected rat Achilles tendons. Journal of Orthopaedic Research. 2003;21:976–983.
  3. Krivic A, et al. BPC-157 and tendon-to-bone healing after Achilles detachment in rats. Journal of Orthopaedic Research. 2006;24(5):982–989.
  4. Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155–1161.
  5. Biçer O, et al. BPC-157 and TB-500 in rat Achilles tendon repair. Joint Diseases and Related Surgery. 2026;37(3).
  6. Staresinic M, et al. BPC-157 and transected quadriceps muscle in rats. Journal of Orthopaedic Research. 2006;24(5):1109–1117.
  7. Novinscak T, et al. BPC-157 and muscle crush injury in rats. Surgery Today. 2008;38:716–725.
  8. Sebecic B, et al. BPC-157 and healing of a segmental bone defect in rabbits. Bone. 1999;24(3):195–202.
  9. Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1–3):33–41.
  10. Hsieh MJ, et al. BPC-157, angiogenesis and VEGFR2 activation. Journal of Molecular Medicine. 2017;95:323–333.
  11. Chang CH, et al. BPC-157, tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology. 2011;110(3):774–780.
  12. Seiwerth S, et al. BPC 157’s effect on healing. Journal of Physiology, Paris. 1997;91(3–5):173–178.
  13. Mikus D, et al. BPC-157 cream, burn-wound healing and burn-associated gastric lesions in mice. Burns. 2001;27(8):817–827.

GHK-Cu studies

  1. Mulder GD, et al. Topical GHK-Cu and diabetic neuropathic ulcer healing. Wound Repair and Regeneration. 1994;2(4):259–269.
  2. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8(4):252–259.
  3. Maquart FX, et al. GHK-Cu and collagen synthesis in fibroblast cultures. FEBS Letters. 1988;238(2):343–346.
  4. Maquart FX, et al. GHK-Cu and connective tissue accumulation in rat wounds. Journal of Clinical Investigation. 1993;92(5):2368–2376.
  5. Parker NP, et al. Topical copper tripeptide complex in an irradiated rat wound model. Otolaryngology–Head and Neck Surgery. 2013;149(3):384–389.
  6. Mao S, et al. GHK-Cu in an experimental model of colitis and its underlying mechanisms. Frontiers in Pharmacology. 2025;16:1551843.
  7. Park JR, et al. GHK-Cu in lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7:58405–58417.

KPV and related alpha-MSH studies

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
  2. Laroui H, et al. Colon-targeted nanoparticles carrying KPV in a mouse colitis model. Gastroenterology. 2010;138(3):843–853.e1–2.
  3. Hiltz ME, Lipton JM. Alpha-MSH peptides inhibit acute inflammation and contact sensitivity. Peptides. 1990;11(5):979–982.
  4. Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233–239.

Thymosin beta-4 studies

  1. Sosne G, Ousler GW. Thymosin beta-4 eye drops in a randomized dry-eye trial. Clinical Ophthalmology. 2015;9:877–884.
  2. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364–368.
  3. Philp D, et al. Thymosin beta-4 and its actin-binding sequence in diabetic and aged mouse wound models. Wound Repair and Regeneration. 2003;11(1):19–24.
  4. Philp D, et al. Thymosin beta-4, hair growth and hair-follicle stem-cell activity. The FASEB Journal. 2004;18(2):385–387.
  5. Bock-Marquette I, et al. Thymosin beta-4, cardiac-cell survival and cardiac repair. Nature. 2004;432:466–472.
  6. Xiong Y, et al. Thymosin beta-4 treatment initiated six hours after traumatic brain injury in rats. Journal of Neurosurgery. 2012;116(5):1081–1092.

Product formula reference

  1. Pure Lab Peptides, KLOW 80 mg product listing. Formula reference checked September 9, 2026.